Combivent

Combivent

ipratropium bromide + salbutamol

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH
Concise Prescribing Info
Contents
Per 2.5 mL Ipratropium Br 0.5 mg, salbutamol sulfate 2.5 mg
Indications/Uses
Management of reversible bronchospasm associated w/ obstructive airway diseases in patients who require more than a single bronchodilator.
Dosage/Direction for Use
Adult including elderly Acute attacks 1 unit-dose vial. Severe cases May require 2nd unit-dose vial to be administered. Maintenance: 1 unit-dose vial tds or qds.
Contraindications
Hypersensitivity to ipratropium Br, salbutamol sulfate or atropine. Hypertrophic obstructive cardiomyopathy or tachyarrhythmia.
Special Precautions
Immediate hypersensitivity reactions. Discontinue use if paradoxical bronchospasm occurs. Patients predisposed to glaucoma; insufficiently controlled DM, recent MI, severe organic heart or vascular disorders, hyperthyroidism, phaeochromocytoma, risk of narrow-angle glaucoma, prostatic hypertrophy or bladder-neck obstruction; underlying severe heart disease eg, ischaemic heart disease, arrhythmia or severe heart failure; hypokalaemia; cystic fibrosis; acute, rapidly worsening dyspnoea. Positive doping test result. Avoid contact w/ eyes. May affect ability to drive & use machines. Hepatic or renal insufficiency. Pregnancy & lactation. Not to be used in childn.
Adverse Reactions
Headache, dizziness; throat irritation, cough; dry mouth, GI motility disorders (eg, constipation, diarrhoea, vomiting), nausea.
Drug Interactions
Increased side effects w/ xanthine derivatives, other β-adrenergics, anticholinergics. Increased β2-agonist induced hypokalaemia w/ glucocorticosteroids, diuretics. Increased susceptibility to arrhythmias w/ digoxin. Potentially serious reduction in bronchodilator effects w/ β-blockers. Enhanced β-adrenergic agonists action w/ MAOIs or TCAs. Increased susceptibility to CV effects of β-agonists w/ halogenated hydrocarbon anaesth eg, halothane, trichloroethylene, enflurane. Not recommended w/ other anticholinergic drugs.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL02 - salbutamol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Combivent nebuliser soln (unit-dose vial)
Packing/Price
2.5 mL x 20 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in